GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cerevel Therapeutics
The historical timeline of Cerevel, a neuroscience-focused biotech, reflected the progress of its clinical development. Its history culminated in its acquisition by AbbVie in 2024, which recognized the potential of its portfolio.
Share prices of companies in the market segment - Neuro
Cerevel Therapeutics is a biopharmaceutical company developing drugs to treat a wide range of neurological disorders, including schizophrenia and Parkinson's disease. We've categorized it under "Neurology." The chart below reflects how investors assess the risks and prospects in this area.
Broad Market Index - GURU.Markets
Cerevel Therapeutics is a biotech company specializing in developing drugs to treat central nervous system disorders, such as Parkinson's disease and schizophrenia. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Cerevel shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
CERE - Daily change in the company's share price Cerevel Therapeutics
For Cerevel Therapeutics, a neuroscience company, daily price change is a measure of its enormous volatility. This metric reflects its extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Neuro
Before its acquisition by AbbVie, Cerevel Therapeutics was a biopharmaceutical company focused on treating neurological diseases. Its history exemplifies how successful biotech developments lead to acquisitions by major players. The chart below illustrates the volatility that drives such interest.
Daily change in the price of a broad market stock, index - GURU.Markets
Cerevel is a biotech company specializing in the treatment of central nervous system diseases. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cerevel Therapeutics
Cerevel Therapeutics' year-over-year performance tells the story of its extensive CNS pipeline. Its market cap change over the past 12 months reflects progress across its numerous clinical programs, as well as its recent acquisition by AbbVie, which fundamentally validated the value of its scientific platform and delivered a premium to shareholders.
Annual dynamics of market capitalization of the market segment - Neuro
Cerevel, a late-stage biotech company developing drugs for the treatment of neurological diseases, is key to its expected acquisition by AbbVie. Its stock price reflects not so much its operating results as the terms of this major deal in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cerevel Therapeutics, a biopharmaceutical company focused on treating brain diseases, is one of the most promising companies in neuroscience. Its annual market capitalization growth is entirely dependent on the success of its extensive development pipeline, making it an interesting yet risky biotech play.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cerevel Therapeutics
Cerevel, a biopharmaceutical company focused on neuroscience. Its monthly performance was entirely dependent on clinical trial results. The chart shows sharp movements driven by trial news, culminating in the announcement of its acquisition by AbbVie at a premium price.
Monthly dynamics of market capitalization of the market segment - Neuro
Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing new treatments for neurological diseases such as schizophrenia and Parkinson's disease. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how its extensive pipeline is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cerevel Therapeutics is a biopharmaceutical company focused on neuroscience. Its shares are buoyed by anticipation of clinical trial results. Their monthly performance is completely disconnected from the broader market, as the chart clearly illustrates, showing a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cerevel Therapeutics
Cerevel Therapeutics, a biopharmaceutical company focused on neuroscience, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials of drugs for schizophrenia and Parkinson's disease, reflecting the high stakes in this complex field.
Weekly dynamics of market capitalization of the market segment - Neuro
Cerevel shares, like those of the entire neuroscience biotech sector, are driven by overall investor sentiment and news of breakthroughs. The success or failure of one major study can impact the entire industry. The chart shows how the company fares against this volatile backdrop.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cerevel Therapeutics is a biotech company focused on neuroscience. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that CERE's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
CERE - Market capitalization of the company Cerevel Therapeutics
Cerevel's chart is a financial map of a new generation of brain drugs. The market capitalization of this Pfizer spinoff reflects the hopes for its extensive pipeline of drugs for schizophrenia, Parkinson's disease, and epilepsy. Its performance is a barometer of the results of its numerous clinical trials in one of the most complex areas of medicine.
CERE - Share of the company's market capitalization Cerevel Therapeutics within the market segment - Neuro
Cerevel Therapeutics, co-founded with Pfizer, is focused exclusively on diseases of the central nervous system. The company's market capitalization in the neuroscience sector reflects the potential of its developments. The company's size reflects its bet on breakthroughs in the treatment of complex diseases such as schizophrenia and Parkinson's disease.
Market capitalization of the market segment - Neuro
Cerevel Therapeutics, backed by Pfizer, develops drugs to treat neurological diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect hopes for a breakthrough in one of the most complex areas of medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cerevel is a biotech company focused on treating diseases of the central nervous system. Its market capitalization chart tells the story of its quest for breakthrough solutions in neurology. Its value reflects both the enormous potential of this market and all the risks associated with developing brain drugs.
Book value capitalization of the company, segment and market as a whole
CERE - Book value capitalization of the company Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company. Its book value represents its R&D capital. The chart below shows its financial resources for developing drugs for neurological diseases. This level is an indicator of its ability to fund its numerous clinical programs.
CERE - Share of the company's book capitalization Cerevel Therapeutics within the market segment - Neuro
Cerevel Therapeutics is a biotech company focused on treating diseases of the nervous system. Its core capital is intellectual property, derived from scientific research. The share of physical assets will reflect its R&D-focused model.
Market segment balance sheet capitalization - Neuro
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Cerevel, which develops drugs for neurological diseases, looks like a "lightweight." Its value lies in its pipeline of promising developments and patents, not in its ownership of large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Cerevel Therapeutics is a biotech company focused on diseases of the nervous system. Its assets are not drugs, but rather a vast pipeline of developments acquired from Pfizer. The company's balance sheet reflects the value of this vast scientific potential, aimed at solving the most complex problems of the real brain.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cerevel Therapeutics
Cerevel's balance sheet is its cash and development pipeline. Its market capitalization represents a huge bet on the success of its neurological drugs. The MvsBCap_Co chart shows how much the "hope" for a new brain drug is worth compared to the cash in its accounts.
Market to book capitalization ratio in a market segment - Neuro
Cerevel Therapeutics, a Pfizer subsidiary, develops drugs for the treatment of central nervous system diseases. Its value lies in its pipeline. The chart shows its high scientific potential, based on clinical trial expectations.
Market to book capitalization ratio for the market as a whole
Cerevel Therapeutics, a Pfizer company, develops drugs to treat neurological diseases. Like other biotechs, its market valuation is a bet on clinical success. This metric demonstrates the premium investors are placing on the potential for a breakthrough in a complex field like brain diseases, ignoring its modest operating balance.
Debts of the company, segment and market as a whole
CERE - Company debts Cerevel Therapeutics
Cerevel Therapeutics, a biopharmaceutical company focused on brain diseases, uses debt to finance its extensive development pipeline. This chart shows how the company is raising significant capital to conduct numerous clinical trials in neurology and psychiatry. Debt here fuels its ambitious research program.
Market segment debts - Neuro
Cerevel Therapeutics is a biotech company specializing in developing drugs to treat central nervous system disorders such as schizophrenia and Parkinson's disease. This is one of the most complex areas in pharmaceuticals. This chart shows how the company funds its large-scale and expensive clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company focused on treating neurological diseases. Its activities are funded in anticipation of future breakthroughs. This chart shows how dependent it is on external capital. It indicates high risk and a significant bet on the ultimate success of its developments.
Market segment debt to market segment book capitalization - Neuro
Cerevel Therapeutics is a biotech company focused on developing drugs to treat nervous system disorders such as Parkinson's disease and schizophrenia. This is one of the most complex areas in medicine. The chart shows how the company's debt load relates to the risks and market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Cerevel Therapeutics (CERE) is a biopharmaceutical company focused on developing treatments for diseases of the central nervous system. Being in the research stage, the company has no revenue. This chart shows the overall debt burden of the market. It serves as a contrast, emphasizing that CERE's future depends on the success of investor-funded R&D.
P/E of the company, segment and market as a whole
P/E - Cerevel Therapeutics
This chart shows the valuation of Cerevel Therapeutics, a biopharmaceutical company focused on diseases of the nervous system. The price-to-earnings ratio is not shown. The company's valuation is based on the potential of its extensive pipeline of developments for the treatment of schizophrenia, epilepsy, and Parkinson's disease. The chart reflects progress in clinical trials.
P/E of the market segment - Neuro
This chart shows the average P/E valuation for biotech companies working in neuroscience. For Cerevel, with its broad development pipeline, it serves as a backdrop. It reflects the overall level of investor confidence in this complex field, providing context for Cerevel's valuation, which is a bet on the success of its science.
P/E of the market as a whole
Cerevel Therapeutics, backed by Pfizer, develops drugs to treat central nervous system disorders such as Parkinson's disease and schizophrenia. It's a highly complex field. This chart shows the sentiment in biotech. It helps understand how the market views Cerevel's scientific approach and its chances of success in a field where many large companies have failed, and the risks involved.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company specializing in developing treatments for diseases of the nervous system. This chart is an indicator of expectations for its extensive clinical pipeline. It reflects analysts' confidence in the company's scientific potential and the future commercial success of its drug candidates.
%20P%2FE%20Cerevel%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cerevel-Therapeutics&v=1772359544616 "Chart of the company's future (projected) P/E Cerevel Therapeutics")
Future (projected) P/E of the market segment - Neuro
Cerevel Therapeutics is a biotech company specializing in developing treatments for nervous system disorders such as Parkinson's disease and schizophrenia. This chart shows average expectations for the biotech sector. CERE's position may indicate the extent to which investors believe in its extensive pipeline and scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772359544619 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cerevel Therapeutics, a Pfizer company, develops drugs for neurological diseases. Its success depends on the results of clinical trials. Being part of a giant, it is less sensitive to sentiment on this chart, but its potential influences the overall valuation of the parent company.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772359544623 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company focused on developing new treatments for neurological diseases such as Parkinson's disease, epilepsy, and schizophrenia. This chart reflects cutting-edge brain research. The losses represent investments in a broad pipeline of developments, while future profits depend on clinical trial success.
Profit of companies in the market segment - Neuro
Cerevel Therapeutics is a biotech company focused on developing drugs to treat neurological disorders such as schizophrenia and Parkinson's disease. Profitability in this sector, as this chart shows, lies in finding breakthroughs in one of the most complex areas of medicine. For CERE, success depends on the ability to create more effective and safer drugs.
Overall market profit
Cerevel Therapeutics, a biopharmaceutical company focused on diseases of the nervous system, is working to solve complex medical problems. The need for treatments for Parkinson's disease or schizophrenia is not dependent on the state of the economy, as this chart shows. The company's success is determined solely by the results of its clinical trials and regulatory approvals.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cerevel Therapeutics
Cerevel Therapeutics, a company co-founded by Pfizer, develops drugs for diseases of the nervous system. This chart reflects analyst forecasts, which are betting on the success of its extensive pipeline of developments in neurology and psychiatry.
%20profit%20of%20the%20company%20Cerevel%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cerevel-Therapeutics&v=1772359544637 "Graph of future (projected) profit of the company Cerevel Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Cerevel Therapeutics is a biotech company spun out of Pfizer, focused exclusively on developing treatments for central nervous system disorders such as schizophrenia and Parkinson's disease. This chart shows the revenue forecast for the neuroscience sector, reflecting the urgent need for new, more effective drugs to treat brain diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772359544639 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cerevel Therapeutics is a biotech company specializing in diseases of the nervous system. Its success depends on the results of clinical trials. The overall economic outlook, reflected in the chart, affects the company indirectly through the willingness of investors and large pharmaceutical companies to finance and acquire risky biotech assets.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772359544639 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cerevel Therapeutics
Cerevel Therapeutics focused on developing drugs to treat nervous system disorders such as schizophrenia and Parkinson's disease. Without commercial revenue, its valuation on this chart reflected solely investors' faith in its scientific pipeline and the potential of its drugs to address enormous medical needs.
P/S market segment - Neuro
Cerevel Therapeutics is a biotech company specializing in developing treatments for central nervous system disorders, such as Parkinson's disease and schizophrenia. The chart shows the average revenue estimate for the biotech company, allowing investors to gauge how highly investors value its neuroscience drug portfolio.
P/S of the market as a whole
Cerevel Therapeutics is a biopharmaceutical company focused exclusively on developing drugs for the treatment of central nervous system disorders, such as schizophrenia and Parkinson's disease. A graph of average market revenue estimates shows that its valuation represents investors' bet on a breakthrough in one of the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cerevel Therapeutics
Cerevel Therapeutics is a biotech company specializing in neuroscience. The chart is a measure of investor optimism regarding its developments. It values the company based on the significant future revenues that its Parkinson's and schizophrenia drugs could generate if approved.
%20P%2FS%20Cerevel%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cerevel-Therapeutics&v=1772359544650 "The graph of the company's future (projected) P/S Cerevel Therapeutics")
Future (projected) P/S of the market segment - Neuro
Cerevel Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as schizophrenia and Parkinson's disease. This figure reflects the average future sales estimate for neuroscience companies. This provides an indication of how highly the market values Cerevel's pipeline and its potential.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772359544651 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Cerevel Therapeutics is a biopharmaceutical company focused on diseases of the nervous system. Its value lies in the potential of its developments. This graph of overall revenue expectations is irrelevant. Investors are focused entirely on clinical trial results, which could lead to breakthroughs in the treatment of Parkinson's and Alzheimer's diseases.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772359544651 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cerevel Therapeutics
Cerevel Therapeutics is a biotech company focused on developing new treatments for neurological diseases such as Parkinson's disease and schizophrenia. While in clinical trials, it typically does not generate sales revenue. This chart will show the future commercial potential of its innovative drugs.
Sales of companies in the market segment - Neuro
Cerevel Therapeutics is a biotech company focused on developing new treatments for neurological and neuropsychiatric diseases, such as Parkinson's disease, epilepsy, and schizophrenia. This chart shows total revenue in the neuroscience sector, reflecting the urgent need and massive investment in drug discovery for brain diseases.
Overall market sales
Cerevel Therapeutics is a biopharmaceutical company specializing in diseases of the central nervous system. Its market capitalization depends on the results of clinical trials. The overall economic situation, reflected in this chart, influences investor willingness to finance risky neuroscience projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cerevel Therapeutics
Cerevel Therapeutics, a spinoff from Pfizer, develops drugs to treat central nervous system disorders such as schizophrenia and Parkinson's disease. Its future depends on the success of its extensive pipeline. The chart reflects market expectations regarding potential breakthroughs in neuroscience.
%20sales%20of%20the%20company%20Cerevel%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cerevel-Therapeutics&v=1772359544658 "Schedule of future (projected) sales of the company Cerevel Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Cerevel Therapeutics is a biotech company focused on developing new treatments for neurological diseases such as Parkinson's disease, schizophrenia, and epilepsy. The chart shows forecasts for the neurological pharmaceutical sector. Cerevel's success depends on breakthroughs in the treatment of the most complex brain diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772359544659 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Cerevel Therapeutics is developing new treatments for neurological diseases such as Parkinson's disease and schizophrenia. The company's success depends on the results of clinical trials. This schedule, reflecting the overall investment climate, affects the availability of capital to fund long-term and expensive neuroscience research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772359544660 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company focused on treating nervous system disorders such as Parkinson's disease and schizophrenia. The company spends heavily on clinical research. This chart illustrates the investment required to develop a new generation of drugs for neurology and psychiatry.
Market segment marginality - Neuro
Cerevel Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. This chart shows the average profitability in the pharmaceutical industry. A strong pipeline of developments targeting large markets such as schizophrenia and Parkinson's disease gives the company the potential to achieve high profitability.
Market marginality as a whole
Cerevel Therapeutics is a biotech company focused on developing drugs for the treatment of nervous system disorders such as schizophrenia and Parkinson's disease. It is in clinical development. This total revenue chart clearly illustrates the difference between a business focused on current profitability and a research-intensive company seeking breakthrough solutions.
Employees in the company, segment and market as a whole
Number of employees in the company Cerevel Therapeutics
Cerevel Therapeutics is a biotech company specializing in developing new treatments for diseases of the central nervous system. This chart shows the size of its team of neuroscientists and clinicians. For a company at this stage, staffing reflects its ability to conduct complex and lengthy clinical trials.
Share of the company's employees Cerevel Therapeutics within the market segment - Neuro
Cerevel Therapeutics, a spinoff from Pfizer, is focused exclusively on developing drugs for diseases of the central nervous system. This is one of the most complex areas in medicine. This chart shows the percentage of the world's leading neuroscientists and clinicians that Cerevel attracts, reflecting its status as a leading think tank in this field.
Number of employees in the market segment - Neuro
Cerevel Therapeutics Holding, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of nervous system disorders. The growth of its scientific and clinical teams, visible in the chart, is an indicator of progress. This increase in staff indicates the active advancement of several drug candidates through clinical trials.
Number of employees in the market as a whole
Cerevel Therapeutics, recently acquired by AbbVie, was developing next-generation drugs for brain disorders such as schizophrenia and Parkinson's disease. The growth of its research team in this chart reflected progress in building a promising pipeline. The staff increase was a signal that caught the attention of the pharmaceutical giant.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cerevel Therapeutics (CERE)
Cerevel Therapeutics is a biopharmaceutical company developing treatments for neurological diseases (such as Parkinson's). Their market capitalization is the market valuation of their pipeline. This chart shows the enormous value investors attribute to this intellectual property portfolio, based on their relatively small team of scientists.
%20of%20the%20company%20Cerevel%20Therapeutics%20(CERE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cerevel-Therapeutics-CERE&v=1772359544669 "Chart of market capitalization per employee (in thousands of dollars) of the company Cerevel Therapeutics (CERE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cerevel Therapeutics is a biotechnology company focused on developing treatments for diseases of the nervous system. Its value is determined solely by the potential of its clinical programs. This chart illustrates how investors value the company's intellectual capital per research scientist.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772359544670 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cerevel Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of nervous system disorders. The chart illustrates its valuation in the complex field of neuroscience. The high market capitalization per employee reflects both the large potential market for such drugs and investors' faith in the company's scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772359544671 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cerevel Therapeutics (CERE)
Cerevel is a biotech company (spinned out of Pfizer) focused on neuroscience (schizophrenia, Parkinson's). The company is profitless. This chart shows the net loss (R&D costs) per scientist working on developing drugs to treat the most complex brain diseases.
%20Chart%20Cerevel%20Therapeutics%20(CERE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cerevel-Therapeutics-CERE&v=1772359544673 "Company Profit Per Employee (in thousands of dollars) Chart Cerevel Therapeutics (CERE)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cerevel Therapeutics is a biotech company specializing in developing drugs to treat nervous system disorders (schizophrenia, Parkinson's disease). This chart shows the company's cash burn per employee. It serves as a benchmark for assessing how intensively the company is investing in its extensive and expensive clinical programs in neurology.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772359544676 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cerevel Therapeutics is a clinical-stage biotech focused on treating severe neurological diseases (schizophrenia, Parkinson's). The company was founded by Pfizer and Bain Capital. This graph shows the company's loss per employee, reflecting its R&D investment in the search for breakthrough drugs for brain diseases.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772359544677 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cerevel Therapeutics (CERE)
Cerevel Therapeutics is a biotech company specializing in diseases of the nervous system. For a company in clinical development, this graph will reflect commercialization milestones. The increase in revenue per employee is likely due to a major partnership with a pharmaceutical giant.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cerevel-Therapeutics-CERE&v=1772359544680 "Sales chart per company employee Cerevel Therapeutics (CERE)")
Sales per employee in the market segment - Neuro
Cerevel (CERE) is a clinical-stage biotech company focused on neurodegenerative diseases (Parkinson's, schizophrenia). The company has no approved products and, therefore, no commercial revenue. This graph doesn't reflect their value. Staff productivity here would be zero, as the entire staff is focused on R&D.
Sales per employee for the market as a whole
Cerevel Therapeutics is a biotech company focused on neuroscience. At the R&D stage, this metric reflects investment in the future. A team of scientists is working on developing a platform, and this metric will only increase with the success of clinical trials and the commercialization of their research.
Short shares by company, segment and market as a whole
Shares shorted by company Cerevel Therapeutics (CERE)
Cerevel (CERE) is a biotech company focused on neuroscience. They are developing drugs for schizophrenia, Parkinson's disease, and epilepsy. This figure reflects bearish bets. Skeptics believe that brain drug development is a "graveyard" for biotech, and their trials are likely to fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cerevel-Therapeutics-CERE&v=1772359544697 "Short Shares Chart for the Company Cerevel Therapeutics (CERE)")
Shares shorted by market segment - Neuro
Cerevel Therapeutics is a biotech company specializing in developing treatments for nervous system disorders such as Parkinson's disease and schizophrenia. This chart shows the overall bearish sentiment across the entire neuroscience biotech sector. This field is known for its high risks, so the surge in short positions in the sector reflects deep investor skepticism about new developments in this field.
Shares shorted by the overall market
Cerevel is a clinical-stage biotech attacking complex neuroscience targets, such as Parkinson's disease. This chart measures general fear. When investors are afraid, they're reluctant to bet on "lottery tickets." They see CERE as a money-burner in a race against giants and sell off shares, unwilling to take scientific risks.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cerevel Therapeutics (CERE)
Cerevel Therapeutics (CERE) is a biotech company spun off from Pfizer, focused exclusively on developing drugs for the treatment of central nervous system disorders (schizophrenia, Parkinson's). This oscillator measures momentum. It shows when the stock is "overheated" (above 70) due to positive trial data or "oversold" (below 30) due to delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cerevel-Therapeutics-CERE&v=1772359544706 "RSI 14 indicator chart for the company's stock Cerevel Therapeutics (CERE)")
RSI 14 Market Segment - Neuro
Cerevel is a "biotech" company, a "brain hunter" (a Pfizer spinoff). They focus on new mechanisms for treating Parkinson's, schizophrenia, and epilepsy. (Acquired by AbbVie). The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the entire segment. It helps us understand: is the CERE acquisition just their R&D or general hype?
RSI 14 for the overall market
Cerevel Therapeutics (CERE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CERE (Cerevel Therapeutics)
Cerevel is a biotech company (founded by Pfizer, acquired by AbbVie) focused on brain diseases (Parkinson's, schizophrenia). This chart shows the average analyst forecast. Their targets are based on clinical data for its portfolio (Tavapadon) and, currently, the price and status of the deal with AbbVie.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CERE-Cerevel-Therapeutics&v=1772359544710 "A chart showing analyst consensus forecasts for the expected stock price. CERE (Cerevel Therapeutics)")
The difference between the consensus estimate and the actual stock price CERE (Cerevel Therapeutics)
Cerevel is Pfizer's legacy in neuroscience. The biotech company is developing a robust R&D pipeline for the treatment of Parkinson's and schizophrenia. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, which is now almost entirely tied to the acquisition price of the giant AbbVie.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CERE-Cerevel-Therapeutics&v=1772359544712 "A chart showing the difference between the consensus forecast and the actual stock price. CERE (Cerevel Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cerevel (CERE) is a biotech company focused exclusively on neuroscience (Parkinson's, schizophrenia). It is a "pure" bet on R&D for treating brain diseases. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe a breakthrough can be achieved in this complex field of medicine.
Analysts' consensus forecast for the overall market share price
Cerevel Therapeutics (CERE) is a blue-blooded biotech company founded by Pfizer and Bain. They are focused on the "holy grail" of treating complex brain diseases such as Parkinson's and schizophrenia. This chart shows the overall risk appetite, reflecting the willingness of investors to fund R&D projects in one of the most complex and risky areas of medicine.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cerevel Therapeutics
Cerevel is an R&D spinoff of Pfizer. It's a biotech R&D company focused entirely on the brain (neurology). Their (massive) pipeline (purchased from Pfizer) targets schizophrenia and Parkinson's. This chart is a pure R&D barometer. It reflects not revenue, but the market's valuation of their (very risky) portfolio and their (critically important) clinical data.
AKIMA Market Segment Index - Neuro
Cerevel (CERE) is a neurobiotech focused on the brain. They are developing a full portfolio of drugs for the treatment of Parkinson's disease, schizophrenia, and epilepsy. This is pure R&D. This chart compares their composite index to the neuropharma sector average.
The AKIM Index for the overall market
Cerevel Therapeutics is a biotech company specializing in neuroscience (schizophrenia, Parkinson's). Spun off from Pfizer and acquired by AbbVie. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this successful story of brain drug development compares to overall economic trends.
